Table 2.
Stepwise Cox regression analyses for prognostic factors.
| Reference | HR (95% CI) | p value | |
|---|---|---|---|
| Progression-free survival | |||
| Time to relapse: 3–6 months | ≥6 months | 1.65 (1.17–2.33) | 0.004 |
| RDI: < 85% | ≥85% | 1.48 (1.05–2.09) | 0.024 |
| Overall survival | |||
| Treatment type: belotecan | Topotecan | 0.69 (0.48–0.99) | 0.045 |
| Time to relapse: 3–6 months | ≥6 months | 2.07 (1.42–3.03) | 0.0002 |
| ECOG PS: 1 | 0 | 1.36 (0.83–2.22) | 0.22 |
| ECOG PS: 2 | 0 | 7.22 (2.05–25.4) | 0.002a |
| Baseline Hb: < 12 g/dL | ≥12 g/dL | 1.54 (1.05–2.26) | 0.028 |
| Baseline Hb: <12 g/dL_LD | ≥12 g/dL_LD | 1.87 (0.82–4.25) | 0.13b |
| Baseline Hb: <12 g/dL_ED | ≥12 g/dL_ED | 1.64 (1.08–2.47) | 0.018b |
ECOG PS Eastern Cooperative Oncology Group performance status, Hb haemoglobin.
aOnly three patients had an ECOG PS of 2.
bp values were calculated using stratified Cox regression analysis.